MGM hallways are really ugly Van I don't know. The room is pretty big but I don't know thisis not classy like Ceasers. (I hope)
Ideas For Now-
- Thread starter stonedinvestor
- Start date
Oh no these gummys make you cry when you watch lost dog reunited with owner videos. Why do I do this to myself...
Woa... China is weird.
Ok Now I have read through all the same news again and under the unfluence of a green gummy I have now found a new idea.
Collier Creek Holdings initiated with a Buy at DA Davidson 07/02 <--- OLD
CCH
DA Davidson analyst Brian Holland initiated coverage of Collier Creek Holdings with a Buy rating and $17 price target pending its combination with Utz Quality Foods and listing as Utz Brands. The analyst believes that the high end of the management's long-term sales guidance of up 4% is "achievable, if not conservative" and also views the management's cost reduction efforts as "credible". Among the drivers for long term organic sales growth, Holland cites the company's more targeted brand investment along with its "white space opportunities across channels, customers, geographies, and sub categories".
This merger just happened.
Utz, Collier Creek complete combination to form Utz Brands 16:07 UTZ, CCH Utz Quality Foods and Collier Creek Holdings (CCH), a special purpose acquisition company, announced that they have completed their business combination. The transaction has been unanimously approved by the board of directors of Collier Creek and was approved at a special meeting of Collier Creek shareholders on August 27. Per the terms of the business combination agreement, Collier Creek and Utz have combined to form Utz Brands, "a leading pure-play snack food platform in the U.S." The common stock of Utz Brands will trade under the ticker symbol "UTZ" on the New York Stock Exchange beginning August 31. Proceeds from the transaction were used primarily to repay existing borrowings at Utz. The Rice and Lissette family, the founding family and owners of Utz, retained more than 90% of its existing equity stake, which represents more than 50% ownership in Utz Brands following completion of the transaction.
Collier Creek Holdings initiated with a Buy at DA Davidson 07/02 <--- OLD
CCH
DA Davidson analyst Brian Holland initiated coverage of Collier Creek Holdings with a Buy rating and $17 price target pending its combination with Utz Quality Foods and listing as Utz Brands. The analyst believes that the high end of the management's long-term sales guidance of up 4% is "achievable, if not conservative" and also views the management's cost reduction efforts as "credible". Among the drivers for long term organic sales growth, Holland cites the company's more targeted brand investment along with its "white space opportunities across channels, customers, geographies, and sub categories".
This merger just happened.
Utz, Collier Creek complete combination to form Utz Brands 16:07 UTZ, CCH Utz Quality Foods and Collier Creek Holdings (CCH), a special purpose acquisition company, announced that they have completed their business combination. The transaction has been unanimously approved by the board of directors of Collier Creek and was approved at a special meeting of Collier Creek shareholders on August 27. Per the terms of the business combination agreement, Collier Creek and Utz have combined to form Utz Brands, "a leading pure-play snack food platform in the U.S." The common stock of Utz Brands will trade under the ticker symbol "UTZ" on the New York Stock Exchange beginning August 31. Proceeds from the transaction were used primarily to repay existing borrowings at Utz. The Rice and Lissette family, the founding family and owners of Utz, retained more than 90% of its existing equity stake, which represents more than 50% ownership in Utz Brands following completion of the transaction.
What up Stoney. Happy Sunday.
Ok, snack foods.
I think I really like this one Stoney. I know UTZ! They make those big ass jars of pretzel nuggets that are filled with peanut butter. Evil good snack. (Muttley will dance around the room on her hind legs like Fred Astaire for one.) That Collier Creek operation, yeah they sold Pinnacle Foods to Con-Agra. Great for Collier, but Con-Agra way overpaid. I remember that deal, pretty sure I traded Mondelez on the pin action of that. It hasn't worked out well at all for $CAG. I bet if they could go back, they wouldn't do it.
Now... Collier is up about 60% since the Street first got wind of this back in June. I guess they'll quit trading under their symbol $CCH Monday. ? New symbol $UTZ. Will it still be $16? I imagine it'll spike up out of the gate. Tough to trade these things on the first day, they can be all over the place.
As an "Idea for now" we'll have to wait until the dust settles. I'm glad you caught it on Cramer, I remember hearing about it earlier this summer but I didn't know Monday was the kickoff.
I did a little research back when it was first announced, as I like the sector because unlike your biotech, its relatively easy to understand. (I remember telling telling folks here to buy Mondelez when it was $38ish as I recall. It's $58 now. Not a grand-slam but still a steady eddie with a nice dividend.)
This move might be more impetus for further consolidation in this sector too. What's left to consolidate that is. One of these days someone will buy MDLZ. Or maybe they'll buy UTZ if Collier works its magic like it did with Pinnacle. Maybe PepsiCo (Frito-Lay) will buy them all. Naaa, Justice Dept won't let that happen, but MDLZ + UTZ.... never know.
Anyway, yeah the CEO of UTZ is a great CEO. He married into the family and worked his way up. Bought up a ton of independent snack makers. Zapps is one. That's a great story too. The guy that started them was an oil dude who went broke. I love stories like that. Good chips if you like em spicey hot. But yeah, the CEO of UTZ is on the move. So its great one for us to watch. I may trade it tommo, we'll see what it acts like. I expect it'll get lots of action. I need to read the details of how many shares etc. I know there's a lot of debt involved. Go figure.
Moving on, that $5 stock you mentioned as a short... these things have borrow rates that make them useless as a short for folks like myself. Plus its just shark infested waters at that point. You can get wiped out shorting things like that. But you are probably right that its not worth much.
GrowGen remains a story stock imo. They can herald 50% revenue growth, but that is coming from their purchase of mom and pops. Where the rubber meets the road, same store sales year over year will ultimately decide where this one is heading. They can probably work those numbers too sooooo.... if it runs, it'll be on Robinhood exuberance type momo. That works too though. Just don't want to be the last one without a chair when the music stops. Think Kodak at $60.
I have not dug into OSUR yet. You've probably got a big winner there, just my gut feeling on that one strictly from knowing you.
Gummies huh(?) ...
Too funny. I guess if they keep the ideas coming...
Go buy a jar of those UTZ pretzel/peanut butter nuggets for when the munchies set in. Toss one to that beast of yours, he'll love it.
Ok, snack foods.
I think I really like this one Stoney. I know UTZ! They make those big ass jars of pretzel nuggets that are filled with peanut butter. Evil good snack. (Muttley will dance around the room on her hind legs like Fred Astaire for one.) That Collier Creek operation, yeah they sold Pinnacle Foods to Con-Agra. Great for Collier, but Con-Agra way overpaid. I remember that deal, pretty sure I traded Mondelez on the pin action of that. It hasn't worked out well at all for $CAG. I bet if they could go back, they wouldn't do it.
Now... Collier is up about 60% since the Street first got wind of this back in June. I guess they'll quit trading under their symbol $CCH Monday. ? New symbol $UTZ. Will it still be $16? I imagine it'll spike up out of the gate. Tough to trade these things on the first day, they can be all over the place.
As an "Idea for now" we'll have to wait until the dust settles. I'm glad you caught it on Cramer, I remember hearing about it earlier this summer but I didn't know Monday was the kickoff.
I did a little research back when it was first announced, as I like the sector because unlike your biotech, its relatively easy to understand. (I remember telling telling folks here to buy Mondelez when it was $38ish as I recall. It's $58 now. Not a grand-slam but still a steady eddie with a nice dividend.)
This move might be more impetus for further consolidation in this sector too. What's left to consolidate that is. One of these days someone will buy MDLZ. Or maybe they'll buy UTZ if Collier works its magic like it did with Pinnacle. Maybe PepsiCo (Frito-Lay) will buy them all. Naaa, Justice Dept won't let that happen, but MDLZ + UTZ.... never know.
Anyway, yeah the CEO of UTZ is a great CEO. He married into the family and worked his way up. Bought up a ton of independent snack makers. Zapps is one. That's a great story too. The guy that started them was an oil dude who went broke. I love stories like that. Good chips if you like em spicey hot. But yeah, the CEO of UTZ is on the move. So its great one for us to watch. I may trade it tommo, we'll see what it acts like. I expect it'll get lots of action. I need to read the details of how many shares etc. I know there's a lot of debt involved. Go figure.
Moving on, that $5 stock you mentioned as a short... these things have borrow rates that make them useless as a short for folks like myself. Plus its just shark infested waters at that point. You can get wiped out shorting things like that. But you are probably right that its not worth much.
GrowGen remains a story stock imo. They can herald 50% revenue growth, but that is coming from their purchase of mom and pops. Where the rubber meets the road, same store sales year over year will ultimately decide where this one is heading. They can probably work those numbers too sooooo.... if it runs, it'll be on Robinhood exuberance type momo. That works too though. Just don't want to be the last one without a chair when the music stops. Think Kodak at $60.
I have not dug into OSUR yet. You've probably got a big winner there, just my gut feeling on that one strictly from knowing you.
Gummies huh(?) ...
Too funny. I guess if they keep the ideas coming...
Go buy a jar of those UTZ pretzel/peanut butter nuggets for when the munchies set in. Toss one to that beast of yours, he'll love it.
Last edited:
If Sportradar is considering going public by merging with a blank check company, it couldn’t pick a better time to be on the market. There are at least six funds actively looking for an acquisition that have the money and the right kind of big-name backers that would make sense in bringing the sports data unicorn to market.
As Sportico exclusively reported two weeks ago, the Switzerland-based company is exploring going public, probably through selling to a blank check company, also known as a special purpose acquisition company, or SPAC. Sportradar provides in-depth sports data to media companies, bookmakers, sports federations and government authorities and has deals with each of the four major North American sports leagues as well as NASCAR and esports league ESL. Founded in 2000, the company has attracted a slate of high-profile private investors, including Mark Cuban, Michael Jordan and Ted Leonsis. The company declined to comment for this article.
Among the funds floated by market participants as potential suitors for Sportradar: hedge fund billionaire Bill Ackman’s Pershing Square Tontine, which last week raised $4 billion, the most-ever by a blank check firm; Starwood billionaire Barry Sternlicht’s Jaws Acquisition; two SPACs formed by investing billionaire Chamath Palihapitiya; and Flying Eagle Acquisition, a SPAC formed by Hollywood executives Jeff Sagansky and Harry Sloan. Just yesterday, Redbird Capital’s Gerry Cardinale and former A’s executive Billy Beane, of Moneyball fame, filed with the SEC to form their own sports-focused SPAC too, named RedBall Acquisition.
SPACs have quickly become a viable alternative to the traditional initial public offering for companies looking to get on the stock market. A sponsor investor forms the SPAC and brings it public by IPO, telling investors it intends to buy a company fitting some broad parameters, such as geographical market or a specific business sector. The entity then has two years to close a deal, otherwise investors who bought the SPAC IPO get their money back, or, if they don’t like the deal struck, simply ask for their cash to be returned.
As Sportico exclusively reported two weeks ago, the Switzerland-based company is exploring going public, probably through selling to a blank check company, also known as a special purpose acquisition company, or SPAC. Sportradar provides in-depth sports data to media companies, bookmakers, sports federations and government authorities and has deals with each of the four major North American sports leagues as well as NASCAR and esports league ESL. Founded in 2000, the company has attracted a slate of high-profile private investors, including Mark Cuban, Michael Jordan and Ted Leonsis. The company declined to comment for this article.
Among the funds floated by market participants as potential suitors for Sportradar: hedge fund billionaire Bill Ackman’s Pershing Square Tontine, which last week raised $4 billion, the most-ever by a blank check firm; Starwood billionaire Barry Sternlicht’s Jaws Acquisition; two SPACs formed by investing billionaire Chamath Palihapitiya; and Flying Eagle Acquisition, a SPAC formed by Hollywood executives Jeff Sagansky and Harry Sloan. Just yesterday, Redbird Capital’s Gerry Cardinale and former A’s executive Billy Beane, of Moneyball fame, filed with the SEC to form their own sports-focused SPAC too, named RedBall Acquisition.
SPACs have quickly become a viable alternative to the traditional initial public offering for companies looking to get on the stock market. A sponsor investor forms the SPAC and brings it public by IPO, telling investors it intends to buy a company fitting some broad parameters, such as geographical market or a specific business sector. The entity then has two years to close a deal, otherwise investors who bought the SPAC IPO get their money back, or, if they don’t like the deal struck, simply ask for their cash to be returned.
KEEP GWPH ON YOUR BOARD... ANALYSTS ARE DUMPING ON THIS NAME...
Saved By Nabiximols-?
GW Pharm's official press release on the Q2 earnings once again gave a lot of attention to the nabiximols opportunity (under the name "Sativex" the drug is already approved in about 25 countries around the world).
Very large potential addressable market for nabiximols if approval goes ahead. This could represent a huge leap from the "orphan drug" status conditions that epidiolex currently treats.
The press release highlighted the expectation of FDA phase 3 trials for nabiximols in the 2nd half of the year for the following conditions:
* MS (multiple sclerosis spasticity). It is interesting that up to 50% of MS patients already self-medicate with cannabis, according to company data.
* Spinal Cord injury.
* PTSD (post-traumatic stress disorder). This condition affects about 11 million people and again is one for which many people self-medicate with various cannabis compounds.b YES YES YES!!!!!!
Spasticity from various sources affects about 3 million people in the USA. If Phase 3 trials commence in Q3, one could be looking at approval in late 2021 and meaningful revenues commencing in 2022.
The company no doubt is very excited about the potential for nabiximols. At the analyst call, CEO Justin Gover (who tends to be conservative in his comments) was quite ebullient:
We believe in Nabiximols' very significant commercial potential over the short, medium and long term... it has the potential to become a broadly used medicine meeting patient needs across numerous indications in the coming years...
Saved By Nabiximols-?
GW Pharm's official press release on the Q2 earnings once again gave a lot of attention to the nabiximols opportunity (under the name "Sativex" the drug is already approved in about 25 countries around the world).
Very large potential addressable market for nabiximols if approval goes ahead. This could represent a huge leap from the "orphan drug" status conditions that epidiolex currently treats.
The press release highlighted the expectation of FDA phase 3 trials for nabiximols in the 2nd half of the year for the following conditions:
* MS (multiple sclerosis spasticity). It is interesting that up to 50% of MS patients already self-medicate with cannabis, according to company data.
* Spinal Cord injury.
* PTSD (post-traumatic stress disorder). This condition affects about 11 million people and again is one for which many people self-medicate with various cannabis compounds.b YES YES YES!!!!!!
Spasticity from various sources affects about 3 million people in the USA. If Phase 3 trials commence in Q3, one could be looking at approval in late 2021 and meaningful revenues commencing in 2022.
The company no doubt is very excited about the potential for nabiximols. At the analyst call, CEO Justin Gover (who tends to be conservative in his comments) was quite ebullient:
We believe in Nabiximols' very significant commercial potential over the short, medium and long term... it has the potential to become a broadly used medicine meeting patient needs across numerous indications in the coming years...
Letter From The Desk of GummyBear Advisors-!
Here at GBA we take very seriously the investing of funds. BUT THAT"S BEFORE THE GUMMY!!!
Don't worry all investments are made and thought through in the early morning. Today we have a lot of politics in the news.
A Trump supporter sprayed Bear spray at someone and was shot dead. This brings Bear spray back into play! And makes me doubt it's worth in a street fight. Other forms of weaponry are going to be important... This Trump supporter was standing up apparently when he fired the bear spray so I'm thinking about Wrap technologies do they sell to the general public?
I have not fired a gun since camp Waganaki (spelled wrong) in Main way back in the 1970's... then I quickly won an award for Pro Marksman! Man that was fun coming home and telling mom I could pick someone off at distance... Smith & Wesson may be an investment here.
At GBA we would rather wrap someone up than shoot them.
Japan is delighted to have Berkshire Hathaway (BRK.A, BRK.B) participate in the future of Japan and the five companies we have chosen for investment," says Warren Buffett. "The five major trading companies have many joint ventures throughout the world and are likely to have more of these partnerships. I hope that in the future there may be opportunities of mutual benefit.
The companies are Itochu, Marubeni, Mitsubishi, Mitsui and Sumitomo. Berkshire says it's been buying shares in the five over the past 12 months, and now has a bit more than a 5% stake in each (that would amount to a total investment of about $6.5B).
I believe it's Mitsubishi Chem that makes Plexiglass....
Here at GBA we take very seriously the investing of funds. BUT THAT"S BEFORE THE GUMMY!!!
Don't worry all investments are made and thought through in the early morning. Today we have a lot of politics in the news.
A Trump supporter sprayed Bear spray at someone and was shot dead. This brings Bear spray back into play! And makes me doubt it's worth in a street fight. Other forms of weaponry are going to be important... This Trump supporter was standing up apparently when he fired the bear spray so I'm thinking about Wrap technologies do they sell to the general public?
I have not fired a gun since camp Waganaki (spelled wrong) in Main way back in the 1970's... then I quickly won an award for Pro Marksman! Man that was fun coming home and telling mom I could pick someone off at distance... Smith & Wesson may be an investment here.
At GBA we would rather wrap someone up than shoot them.
Japan is delighted to have Berkshire Hathaway (BRK.A, BRK.B) participate in the future of Japan and the five companies we have chosen for investment," says Warren Buffett. "The five major trading companies have many joint ventures throughout the world and are likely to have more of these partnerships. I hope that in the future there may be opportunities of mutual benefit.
The companies are Itochu, Marubeni, Mitsubishi, Mitsui and Sumitomo. Berkshire says it's been buying shares in the five over the past 12 months, and now has a bit more than a 5% stake in each (that would amount to a total investment of about $6.5B).
I believe it's Mitsubishi Chem that makes Plexiglass....
People often ask GBA what are your indicators you are always shouting about. Well the answer is we have so many! But one good one is The Common Sense Indicator, we call it CSI.
CSI Moment #1-- Stock Splits. Hey it's great and makes sense when a high flyer splits their stock and many more people can afford to buy some. But the concept has been watered down with these Index funds haven't it? Why would an $19 stock split though?- That happened today, I lost track of the name but a $19 stk is splitting... and it's like 4 for 1... WARNING WARNING!
Today I thought I'd let all interested parties listen in on an actual Morning Roundtable here at GummyBear Advisors.. and with that I'd like to turn this conference call over to our VP of Trades.
Hello Everyone! Wind wind wind. It's everywhere and nowhere. Thank you.
That's it?
Broadwind sees 2020 revenue approx. $200M, and consensus $203.74M - That's a slight miss but we don't care we like BWEN. The CEO said
While the timing of wind tower orders can vary from quarter to quarter, our tower backlog remains at elevated levels, providing improved visibility as we look ahead to 2021," stated Eric Blashford, President and CEO of Broadwind. "While the impact of COVID-19 has pushed some customer orders out into early next year, all indications are that tower demand activity is expected to remain strong over the next twelve months, given the overall strength of the wind market supported by the recent Production Tax Credit safe-harbor extension. For the full-year 2020, we anticipate revenue of approximately $200 million, together with double digit percent year-over-year growth in Adjusted EBITDA, supported by our ongoing diversification efforts and a stable outlook within our core clean tech markets."
Ok Good one. What else.
Well Carrier keeps doing good things. They are working with some schools to bring fresh safe air into the classrooms. And now they are working with Cushman & Wakefield.
Carrier Global, Cushman & Wakefield to collaborate to enhance health, safety CARR, CWK Carrier Global (CARR) and Cushman & Wakefield (CWK) have agreed to collaborate to introduce Carrier's premier healthy building solutions for Cushman & Wakefield's clients through Carrier's Healthy Buildings Program. The pandemic has intensified the urgency and need for solutions that help provide a safe return to the office. This strategic collaboration will allow Carrier to provide Cushman & Wakefield clients the tools to assess a building's readiness for occupancy, upgrade applicable advanced technologies and optimize indoor environments to be safer, healthier and more efficient. Carrier's Healthy Buildings Program offering can benefit Cushman & Wakefield clients through a broad portfolio of advanced services and technologies - from improving indoor air quality, delivering remote services to managing ventilation in buildings and implementing touchless solutions. The collaboration is under a memorandum of understanding whose terms are non-binding and are subject to negotiation of mutually acceptable technical and commercial terms and conditions."
This seems like an ongoing trend that will last many years. CARR has moved form $23-$30 already so we feel this is a pick up on a pull back.
Thank you.. wait I'm being handed a note...Broadwind announces approx. $21M in wind tower orders from existing customer <-- This came after the last release... so we add this to the PR that said they slightly missed-- with this they beat.. Am I correct? What strange timing.
Is Bio B here?
Yes sir.
Have at it.
Piper Sandler a buyer of Akebia into Phase 3 vadadustat data AKBA .
This is the same stock you lost so much money in?
Yes Sir the same stock we have held for like ten years. With a huge loss.
What else?
Nestle a food company apparently bought a biotech?
Aimmune jumps 170% to $34.01 after Nestle acquires for $34.50 per share Nestle acquires Aimmune for $34.50 per share in cash or $2.6B » 04:46 AIMT, Aimmune Therapeutics…
My God 170% gain.... Is there any Biotech now that could give us that?
Perhaps, Piper Sandler 'blown away' by NGM Biopharmaceuticals new data from EASL 18:51 NGM Piper Sandler analyst Yasmeen Rahimi notes that NGM Biopharmaceuticals finished EASL conference "strong" with several highly anticipated data points showing aldafermin's clear antifibrotic benefit in F3 patients as well as cardiovascular safety. The analyst believes this not only increases the Probability of Success of Phase 2b ALPINE 2/3 in F2/F3 patients, but also provides evidence for aldafermin's efficacy and safety in patients varying degrees of fibrosis severity with potential readthrough to cirrhotic patients in the Phase 2b ALPINE 4 study. Rahimi has an Overweight rating and a $30 price target on the shares.
$30? The stock is only what $18?
NGM presents data from 24-week Phase 2 study of aldafermin 1 mg NGM Biopharmaceuticals announced that final data from its 24-week Phase 2 study of aldafermin 1 mg in patients with non-alcoholic steatohepatitis were featured in a late-breaker oral plenary presentation at The Digital International Liver Congress 2020. The presentation included a new analysis of Cohort 4 data from NASH patients with stage 3 liver fibrosis demonstrating that 1 mg aldafermin had a potent anti-fibrotic effect in these patients with more advanced disease.
Interesting. This could be a two year hold?
Yes. NGM also announced today that it has completed enrollment in its ongoing Phase 2b ALPINE 2/3 study of 0.3 mg, 1 mg and 3 mg aldafermin versus placebo in patients with biopsy-confirmed NASH with stage 2 and F3 liver fibrosis. The primary objective of the ALPINE 2/3 study is to evaluate a dose response showing an improvement in liver fibrosis by greater than or equal to 1 stage with no worsening of steatohepatitis at Week 24. NGM expects to report topline findings from the study in the second quarter of 2021.
Also, efficacy data from a new secondary analysis of patients with advanced liver fibrosis enrolled in the 24-week Phase 2 study were included in the aldafermin presentation at Digital ILC. In this patient population, 30% of patients with F3 liver fibrosis treated with aldafermin 1 mg achieved fibrosis improvement greater than 1 stage without worsening of NASH compared to 0% in the placebo arm.
Excuse me?
A responder analysis conducted in patients with F3 liver fibrosis who achieved greater than or equal to 30% LFC reductions showed that 46% of patients treated with aldafermin 1 mg had fibrosis improvement of greater than or equal to 1 stage without worsening of NASH compared to 0% of placebo patients.
You Mean you can Be stage 3 and go backwards to stage 2?
Yes sir NGM is a buy.
Ok very interesting Thank you. This wraps up our Inside look at the machinations behind GummyBearAdvisors.....
CSI Moment #1-- Stock Splits. Hey it's great and makes sense when a high flyer splits their stock and many more people can afford to buy some. But the concept has been watered down with these Index funds haven't it? Why would an $19 stock split though?- That happened today, I lost track of the name but a $19 stk is splitting... and it's like 4 for 1... WARNING WARNING!
Today I thought I'd let all interested parties listen in on an actual Morning Roundtable here at GummyBear Advisors.. and with that I'd like to turn this conference call over to our VP of Trades.
Hello Everyone! Wind wind wind. It's everywhere and nowhere. Thank you.
That's it?
Broadwind sees 2020 revenue approx. $200M, and consensus $203.74M - That's a slight miss but we don't care we like BWEN. The CEO said
While the timing of wind tower orders can vary from quarter to quarter, our tower backlog remains at elevated levels, providing improved visibility as we look ahead to 2021," stated Eric Blashford, President and CEO of Broadwind. "While the impact of COVID-19 has pushed some customer orders out into early next year, all indications are that tower demand activity is expected to remain strong over the next twelve months, given the overall strength of the wind market supported by the recent Production Tax Credit safe-harbor extension. For the full-year 2020, we anticipate revenue of approximately $200 million, together with double digit percent year-over-year growth in Adjusted EBITDA, supported by our ongoing diversification efforts and a stable outlook within our core clean tech markets."
Ok Good one. What else.
Well Carrier keeps doing good things. They are working with some schools to bring fresh safe air into the classrooms. And now they are working with Cushman & Wakefield.
Carrier Global, Cushman & Wakefield to collaborate to enhance health, safety CARR, CWK Carrier Global (CARR) and Cushman & Wakefield (CWK) have agreed to collaborate to introduce Carrier's premier healthy building solutions for Cushman & Wakefield's clients through Carrier's Healthy Buildings Program. The pandemic has intensified the urgency and need for solutions that help provide a safe return to the office. This strategic collaboration will allow Carrier to provide Cushman & Wakefield clients the tools to assess a building's readiness for occupancy, upgrade applicable advanced technologies and optimize indoor environments to be safer, healthier and more efficient. Carrier's Healthy Buildings Program offering can benefit Cushman & Wakefield clients through a broad portfolio of advanced services and technologies - from improving indoor air quality, delivering remote services to managing ventilation in buildings and implementing touchless solutions. The collaboration is under a memorandum of understanding whose terms are non-binding and are subject to negotiation of mutually acceptable technical and commercial terms and conditions."
This seems like an ongoing trend that will last many years. CARR has moved form $23-$30 already so we feel this is a pick up on a pull back.
Thank you.. wait I'm being handed a note...Broadwind announces approx. $21M in wind tower orders from existing customer <-- This came after the last release... so we add this to the PR that said they slightly missed-- with this they beat.. Am I correct? What strange timing.
Is Bio B here?
Yes sir.
Have at it.
Piper Sandler a buyer of Akebia into Phase 3 vadadustat data AKBA .
This is the same stock you lost so much money in?
Yes Sir the same stock we have held for like ten years. With a huge loss.
What else?
Nestle a food company apparently bought a biotech?
Aimmune jumps 170% to $34.01 after Nestle acquires for $34.50 per share Nestle acquires Aimmune for $34.50 per share in cash or $2.6B » 04:46 AIMT, Aimmune Therapeutics…
My God 170% gain.... Is there any Biotech now that could give us that?
Perhaps, Piper Sandler 'blown away' by NGM Biopharmaceuticals new data from EASL 18:51 NGM Piper Sandler analyst Yasmeen Rahimi notes that NGM Biopharmaceuticals finished EASL conference "strong" with several highly anticipated data points showing aldafermin's clear antifibrotic benefit in F3 patients as well as cardiovascular safety. The analyst believes this not only increases the Probability of Success of Phase 2b ALPINE 2/3 in F2/F3 patients, but also provides evidence for aldafermin's efficacy and safety in patients varying degrees of fibrosis severity with potential readthrough to cirrhotic patients in the Phase 2b ALPINE 4 study. Rahimi has an Overweight rating and a $30 price target on the shares.
$30? The stock is only what $18?
NGM presents data from 24-week Phase 2 study of aldafermin 1 mg NGM Biopharmaceuticals announced that final data from its 24-week Phase 2 study of aldafermin 1 mg in patients with non-alcoholic steatohepatitis were featured in a late-breaker oral plenary presentation at The Digital International Liver Congress 2020. The presentation included a new analysis of Cohort 4 data from NASH patients with stage 3 liver fibrosis demonstrating that 1 mg aldafermin had a potent anti-fibrotic effect in these patients with more advanced disease.
Interesting. This could be a two year hold?
Yes. NGM also announced today that it has completed enrollment in its ongoing Phase 2b ALPINE 2/3 study of 0.3 mg, 1 mg and 3 mg aldafermin versus placebo in patients with biopsy-confirmed NASH with stage 2 and F3 liver fibrosis. The primary objective of the ALPINE 2/3 study is to evaluate a dose response showing an improvement in liver fibrosis by greater than or equal to 1 stage with no worsening of steatohepatitis at Week 24. NGM expects to report topline findings from the study in the second quarter of 2021.
Also, efficacy data from a new secondary analysis of patients with advanced liver fibrosis enrolled in the 24-week Phase 2 study were included in the aldafermin presentation at Digital ILC. In this patient population, 30% of patients with F3 liver fibrosis treated with aldafermin 1 mg achieved fibrosis improvement greater than 1 stage without worsening of NASH compared to 0% in the placebo arm.
Excuse me?
A responder analysis conducted in patients with F3 liver fibrosis who achieved greater than or equal to 30% LFC reductions showed that 46% of patients treated with aldafermin 1 mg had fibrosis improvement of greater than or equal to 1 stage without worsening of NASH compared to 0% of placebo patients.
You Mean you can Be stage 3 and go backwards to stage 2?
Yes sir NGM is a buy.
Ok very interesting Thank you. This wraps up our Inside look at the machinations behind GummyBearAdvisors.....